- Home » News and EventsPage 16
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Advantages of Oncolytic Viruses as Immunotherapies to be Discussed by Catalent Gene Therapy Expert
Sep 22, 2020
Catalent today announced that George Buchman, Ph.D., Vice President, Preclinical & Process Development, will present at the World Vaccine Congress, which will take place virtually on Sept. 28 – October 1, 2020.
T-knife and Catalent Sign Technology Transfer and Manufacturing Agreement for Autologous T-Cell Receptor-Based Cell Therapy
Sep 21, 2020
T-knife and Catalent today announced they have signed an agreement to provide technology transfer and CGMP clinical manufacturing of T-knife’s T1367 T-cell receptor (TCR) program.
Catalent Biologics and Humanigen to Present a Case Study on Accelerated Scale Up of a Monoclonal Antibody to Treat COVID-19 at BioProcess International Conference
Sep 16, 2020
Catalent today announced that it will present at the upcoming BioProcess International virtual conference, taking place between Sept. 21 – 25, 2020.
RheinCell Therapeutics Achieves Milestone GMP Certification to Manufacture Cord Blood-Derived iPSCs for Safe and Compliant Cell Therapies
Sep 15, 2020
We are proud to announce that Rheincell has GMP certification and Manufacturing Authorization to supply clinical-grade iPSCs and thus, make a meaningful contribution to advancing cell therapies
Modern Clinical Supply Strategies and Ensuring Effective Solutions to be Discussed by Catalent Experts at GCSG Virtual
Sep 15, 2020
Catalent today announced that it will lead multiple workshops and exhibit at the upcoming Global Clinical Supplies Group (GCSG) 2020 Global Virtual Conference, which takes place on Sept. 21-25, 2020.
Catalent to be Added to S&P 500® Index
Sep 11, 2020
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today welcomed the news that the company is being added to the iconic S&P 500® index published by S&P Dow Jones Indices.
Catalent Invests $130 Million to Add Additional Manufacturing Capacity at its Gene Therapy Campus in Harmans, Maryland
Sep 9, 2020
Catalent today announced that it is investing $130 million to add five additional Phase 3 through commercial-scale manufacturing suites to its gene therapy campus in Harmans, Maryland.
Exelixis and Catalent Enter into Collaboration, License, and Exclusive Option Agreement to Develop Antibody-Drug Conjugates Leveraging SMARTag® Bioconjugation Technology
Sep 8, 2020
Exelixis, Inc. and Catalent today announced a partnership under which Catalent will develop multiple ADCs for Exelixis using Catalent’s proprietary SMARTag® technology.
Catalent Biologics Invests $50 Million to Add Third High-Speed Vial Line at its Bloomington, Indiana, Facility
Sep 2, 2020
Catalent today announced that it is investing $50 million to install an additional high-speed vial filling line at its Bloomington, Indiana, facility.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.